Document Detail


Impaired energetics in heart failure - a new therapeutic target.
MedLine Citation:
PMID:  18602947     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Heart failure is a syndrome of huge and growing importance worldwide. It is widely accepted that the energy status of the myocardium in heart failure is impaired, irrespective of etiology. Agents which modify cardiac substrate utilisation have the potential to ameliorate this energy deficiency by increasing cardiac mechanical efficiency. This may represent a new therapeutic paradigm in heart failure. In this review we discuss existing and new agents that alter cardiac substrate use and summarise the data on clinical efficacy.
Authors:
Julian O M Ormerod; Houman Ashrafian; Michael P Frenneaux
Related Documents :
3916797 - Acute right heart failure.
16911907 - Ancient egyptian medicine and the concept of heart failure.
7248827 - Metastatic myocardial calcification.
11543157 - Application of statistical physics to heartbeat diagnosis.
24642387 - Malignant ventricular arrhythmias after off-pump coronary artery bypass.
2189307 - Thyroid hormone and the cardiovascular system.
Publication Detail:
Type:  Journal Article; Review     Date:  2008-06-17
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  119     ISSN:  0163-7258     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-08     Completed Date:  2009-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  264-74     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, University of Birmingham, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Carbohydrate Metabolism / drug effects
Energy Metabolism / drug effects*
Heart Failure / drug therapy*,  metabolism,  physiopathology
Humans
Models, Biological
Myocardium / metabolism*,  pathology
Oxidation-Reduction / drug effects

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent trends in U.S. mammography use from 2000-2006: a population-based analysis.
Next Document:  Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.